Emma Walmsley has also been busy shaking up the company and has replaced 50 top managers, around 40% of the company’s management. Pfizer said in October that it is considering selling its ...
GSK Plc is a long-term underperformer among Europe’s Big Pharma stocks. And with key drug patents set to expire and vaccine ...
GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...
The pharma giant has operated in Ireland for decades and continues to have operations in key locations such as Cork and ...
GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 billion, betting that growing sales of its HIV and cancer drugs will make ...
While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...
GSK plc (LON:GSK – Get Free Report) insider Emma Walmsley sold 120,653 shares of the firm’s stock in a transaction on Monday, ...
Chief executive Emma Walmsley said ministers must work with the sector to boost investment amid growing concerns about doing ...
GSK launched a rare £2bn share buyback and raised its growth targets on the back of strong sales of speciality medicines, including cancer and HIV drugs, sending shares up as much as 6 per cent on ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback